Business Insider10d
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
RUTHERFORD, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and ...
Drug Delivery Business10d
Glucotrack completes first-in-human continuous blood glucose monitor implant study
Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose ...
Nasdaq9d
Glucotrack, Inc. Announces Pricing of $3.0 Million Public Offering
Rutherford, NJ., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical technology company focused on the design, development, and ...
Morningstar10d
Glucotrack Announces Successful Completion of Its First Human Clinical Study of Continuous Blood Glucose Monitor
(“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced the ...